Table 2.

The differences in parameters between patients with VT resulting in ATP vs. patients without VT resulting in ATP during follow-up

Proposed risk factors	VT resulting in ATP n = 15	No VT resulting in ATP n = 31	P-value
Age mean ± SD	55.5 ± 13.3	53.2 ± 11.4	0.59
Age at diagnosis mean ± SD	41.6 ± 13.8	40.2 ± 12.0	0.35
Male n (%)	11 (73.3)	17 (54.8)	0.34
Diabetes mellitus n (%)	0 (0)	3 (9.7)	0.54
Hypertension n (%)	5 (33.3)	8 (25.8)	0.73
Ischaemic heart disease n (%)	1 (6.7)	0 (0)	1.00
Atrial fibrillation n (%)	2 (13.3)	6 (19.4)	0.33
Bundle branch block n (%)	2 (13.3)	7 (22.6)	0.70
Anti-arrhythmic drugs n (%)	10 (66.7)	18 (58.1)	0.75
Sotalol n (%)	8 (80.0)	10 (55.6)	0.21
Flecainide n (%)	2 (20.0)	3 (16.7)	1.00
Amiodarone n (%)	0 (0)	5 (27.8)	0.16
Left ventricular function ≥55% n (%)	8 (53.3)	16 (51.6)	1.00
Left ventricular involvement n (%)	7 (46.7)	15 (48.4)	1.00
Severe ventricular impairment n (%)
RV function n (%)	12 (80.0)	1 (3.2)	<0.001
LV function n (%)	3 (20.0)	4 (12.9)	0.67
Severely ventricular dilatation n (%)			<0.001
RV size n (%)	9 (60.0)	3 (9.7)	<0.001
LV size n (%)	2 (13.3)	2 (6.5)	0.59
Right ventricle aneurysm n (%)	1 (6.7)	1 (3.2)	1.00
Gene status n (%)	14 (93.3)	21 (67.7)	0.07
DSP n (%)	2 (14.3)	11 (52.4)	0.03
PKP2 n (%)	10 (71.4)	3 (14.3)	0.001

DSP, desmoplakin; LV, left ventricle; PKP2, plakophilin 2; RV, right ventricle.